Basis: Four-quarter free cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The free cash flow yield is N/A as of 2026-10-06T14:56:23.021Z.
Calculation as of: 2026-10-06T14:56:23.021Z.
Quote observation: 2026-10-06T14:55:20.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 979ff17a100a324a490b4ea8bab969f4c23ca35a684dd985742eca9c7cd70937
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2024-09-30.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FREE CASH FLOW YIELD
N/A
FREE CASH FLOW YIELD AVG TTM
N/A
FREE CASH FLOW YIELD AVG 3Y
N/A
FREE CASH FLOW YIELD AVG 5Y
N/A
FREE CASH FLOW YIELD AVG 10Y
N/A
FREE CASH FLOW YIELD AVG 15Y
N/A
FREE CASH FLOW YIELD AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$640.57M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$610.07M
Free Cash Flow Yield
0.08%
TTM Avg
0.21%
3Y Avg
0.21%
5Y Avg
0.70%
Market Cap
$665.40M
Free Cash Flow Yield
6.10%
TTM Avg
8.57%
3Y Avg
5.30%
5Y Avg
5.30%
Market Cap
$666.36M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$600.96M
Free Cash Flow Yield
N/A
TTM Avg
2.13%
3Y Avg
14.68%
5Y Avg
12.04%
Market Cap
$597.83M
Free Cash Flow Yield
31.04%
TTM Avg
16.53%
3Y Avg
24.36%
5Y Avg
19.94%
| NAME | MARKET CAP | FREE CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Climb Bio, Inc. (CLYM) | $636.48M | N/A | N/A | N/A | N/A |
| Aura Biosciences, Inc. (AURA)vs › | $640.57M | N/A | N/A | N/A | N/A |
| OmniAb, Inc. (OABI)vs › | $643.45M | N/A | 0.14% | 0.13% | 0.13% |
| AngioDynamics, Inc. (ANGO)vs › | $610.07M | 0.08% | 0.21% | 0.21% | 0.70% |
| MiMedx Group, Inc. (MDXG)vs › | $665.40M | 6.10% | 8.57% | 5.30% | 5.30% |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $666.36M | N/A | N/A | N/A | N/A |
| Helus Pharma Inc. (HELP)vs › | $666.95M | N/A | N/A | N/A | N/A |
| Fulgent Genetics, Inc. (FLGT)vs › | $600.96M | N/A | 2.13% | 14.68% | 12.04% |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $597.83M | 31.04% | 16.53% | 24.36% | 19.94% |
| Annexon, Inc. (ANNX)vs › | $679.13M | N/A | N/A | N/A | N/A |
FCF Yield
N/A
Earnings Yield
N/A
Dividend Yield
N/A
Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100
How FCF Yield is used:
FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.
FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | FREE CASH FLOW YIELD |
|---|---|
| 2024-09-30 | 0.04% |
| 2024-09-27 | 0.04% |
| 2024-09-26 | 0.04% |
| 2024-09-25 | 0.03% |
| 2024-09-24 | 0.03% |
| 2024-09-23 | 0.02% |
| 2024-09-20 | 0.02% |
| 2024-09-19 | 0.02% |
| 2024-09-18 | 0.02% |
| 2024-09-17 | 0.02% |
| 2024-09-16 | 0.02% |
| 2024-09-13 | 0.02% |
| 2024-09-12 | 0.02% |
| 2024-09-11 | 0.02% |
| 2024-09-10 | 0.02% |
| 2024-09-09 | 0.02% |
